Sunday, May 25, 2025 12:16:14 PM
Vin, you should read the scientific research articles rather than message boards if you want to better understand the life cycle of the various viruses. There will be a residual number of deaths each week from Covid for the foreseeable future.
Biotech_"researcher",
You should take your own advice as you clearly know little to nothing of viruses or science. For example, you foolishly wrote the life cycle of viruses rather than the seasonality of Covid spread, or more precisely, the epidemiology of Covid transmission. The life cycle of virus refers to how the virus enters the cell, hijacks the cellular machinery to reproduce and then exits the cell as large numbers of newly created infectious virions. The number of deaths from Covid will be determined by the multiple factors, the inherent lethality of the virus and the ease of spread which has a number of variables, one of which is the immunity levels in the population. Given that Covid mutates so that new variants emerge, it is hard to predict how future waves of Covid will affect the human population, especially since Covid has animal hosts. Consequently, it is extremely foolish and the height of arrogance to state there will only be residual Covid deaths in the foreseeable future as you did. By the way, you left off the tens of millions suffering from what is termed long Covid.
Your ignorance on all these topics and likely reliance on message boards rather than scientific literature led you to post the following
Flo, I can't imagine ANY human EVER taking another injection of a Covid vaccine again.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=176219764
Recent ENTA News
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/13/2026 11:25:49 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2026 11:00:39 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/11/2026 08:05:17 PM
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 • Business Wire • 05/11/2026 08:01:00 PM
- Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026 • Business Wire • 05/04/2026 11:00:00 AM
- Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria • Business Wire • 04/13/2026 11:00:00 AM
- Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026 • Business Wire • 04/07/2026 11:00:00 AM
- Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) • Business Wire • 03/30/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/26/2026 12:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:20:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:18:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:17:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/13/2026 08:14:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/12/2026 08:05:29 PM
- Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference • Business Wire • 03/03/2026 12:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/23/2026 05:15:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:33:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:31:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:29:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:28:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2026 09:27:26 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/11/2026 09:43:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/11/2026 09:00:44 PM
- Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting • Business Wire • 02/10/2026 12:00:00 PM
